We loaded the GPX-4 inhibitor RSL3 into RMPs to investigate the potential for a synergistic effect of GPX-4 inhibition and RMPs on ferroptosis to treat prostate cancer. The gene discussed is GPX4; the disease is prostate carcinoma.